Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT For the transition period from __________to__________ Commission File No. 001-39801 XOMA Corporation (Exact name of registrant as specified in its charter) Delaware 52-2154066 (State or other ju ...

公司概况 - 拥有超70项资产，涉及超30种已披露适应症且数量在增加，合作方包括罗氏、诺华等[8] - 收购与中早期临床候选药物相关的药品特许权，专注有潜力成重磅炸弹且授权给大型合作伙伴的资产[8] 资产进展 - 自2017年以来，投资组合有超25项从一个阶段推进到下一阶段，如2项获FDA批准等[13] - 目前组合中各阶段项目数量为临床前6项、1期1项、1/2期24项等[15] 特许权费率 - 如Faricimab 1特许权费率为0.5%，NIS793为中个位数到低两位数等[16] 临床事件预期 - 2022 - 2023年上半年有众多潜在由合作伙伴推动的临床事件，如Rezolute/RZ358预计启动3期等[23] 收购交易 - 2018 - 2021年有多项收购交易，如Affitech项目投入1100万美元等[32] 财务亮点 - 近期运营亮点包括以600万美元收购罗氏faricimab经济权益等，完成超6000万美元永久优先股发行[38] 合作资产动态 - 罗氏新型双特异性抗体获FDA批准用于治疗nAMD/DME，诺华启动NIS793 3期研究等[45] 组合潜力 - 中期、中后期和早期阶段资产潜在里程碑超10亿美元[52][60][63][66]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT For the transition period from __________to__________ Commission File No. 001-39801 XOMA Corporation (Exact name of registrant as specified in its charter) Delaware 52-2154066 (State or other jurisdi ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT (Exact name of registrant as specified in its charter) Delaware 52-2154066 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) 2200 Powell Street, Sui ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39801 XOMA CORPORATION (Exact name of registrant as specified in its charter) Delaware 52-2154066 (State or other jurisdiction ...

公司概况 - 拥有超70项资产组合，涉及超30种已披露适应症且数量在增长，合作方包括罗氏、诺华等[8] - 收购与中早期临床候选药物相关的药品特许权，专注有潜力的开发阶段资产[8] 资产进展 - 自2017年以来，资产组合有超25项从一个阶段推进到下一阶段，如2项获FDA批准等[13] - 2021年有多起合作驱动的临床事件，如罗氏faricimab1的BLA获FDA受理等[22] - 2022年预计有多项合作驱动的临床事件，如Rezolute/RZ358的2期CHI数据公布等[25] 资产权益 - 从Affitech SA获得经济权益，如罗氏faricimab1的0.5%特许权费率[16] - 多项资产有不同特许权费率，如诺华NIS793为中个位数到低两位数[16] 财务与交易 - 2018 - 2021年有多起收购交易，资本投入从120万美元到1500万美元不等[36] - 近期运营亮点包括获得罗氏faricimab经济权益、完成超6000万美元永久优先股发行等[40] 市场机会 - 2014 - 2020年行业许可交易共3817笔，其中3期514笔、2期646笔等[32] 资产潜力 - 多个阶段资产潜在里程碑超10亿美元（部分资产未包含）[50][52][62][65]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT For the transition period from __________to__________ Commission File No. 001-39801 XOMA Corporation (Exact name of registrant as specified in its charter) Delaware 52-2154066 (State or other ju ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT For the transition period from __________to__________ Commission File No. 001-39801 XOMA Corporation (Exact name of registrant as specified in its charter) Delaware 52-2154066 (State or other jurisdi ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q 2200 Powell Street, Suite 310 Emeryville, California 94608 (Address of principal executive offices) (Zip Code) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT For the transition period from __________to__________ Commission File No. 001-39801 XOM ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 0-14710 XOMA CORPORATION (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or o ...